FDA Rare Disease Innovation Hub: Enhancing Collaboration and Speed?
In 2023, over half of all the novel drugs and biologics approved by the FDA’s Center for Drug Evaluation and Research (CDER) and the FDA’s Center for Biologics Evaluation and Research (CBER) were to prevent, diagnose or treat a rare disease or condition. The recently-formed FDA Rare Disease Innovation Hub is a new model of collaboration between CDER and CBER – and a key indicator of their commitment to explore new approaches for the development and approval of safe and effective drugs and biologics for rare diseases.
This webinar discussion focuses on the desired priorities and potential outcomes of this initiative from the perspectives of the rare disease clinical research community – including those of a rare disease clinician, former FDA regulator and rare disease clinical research scientists. Key questions raised in this discussion include:
- What outcomes are most important for the research community? For patients and their families? What are the top priorities for improvement from the drug development ecosystem in support of rare disease?
- Which longstanding challenges are most critical for the FDA to address and why? What resources are needed to help solve these challenges?
- Are there similar regulatory initiatives that are helping the FDA keep pace with drug development complexity and the recent breakthroughs in genetic science, personalized medicine and novel therapies? What learnings and advancements are currently being applied to the rare disease space or can be?
- What emerging practices and development approaches are likely here to stay? What expanded role can the research community take in partnering with the FDA and how?
Related Insights
Audiogram
New FDA regulatory initiatives improving rare disease drug development
Sep 23, 2025
Podcast
Rare endpoints: Delivering on unmet patient needs
May 7, 2024
Blog
Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress
May 2, 2024
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Case Study
Speed meets strategy: Delivering a critical FDA 1572 package in just seven days
Sep 9, 2026
Blog
Actioning the commitment letter: The PDUFA VIII changes that matter most to sponsors
Aug 25, 2026
Blog
Data without borders: Assessing China-only evidence for EMA approval – insights from ex-EMA and seasoned subject matter experts
Aug 19, 2026
Blog
The Next Frontier of ADC Development: Navigating an Evolving Regulatory Landscape
Aug 12, 2026
Blog
Japan: the new strategic launchpad for accelerating global rare disease development
Jul 23, 2026
Webinar
From APAC to Global: Designing Data that Travels
Jul 16, 2026
Blog
Regulatory submissions as a source of insight: How AI can amplify the value of our work
Jul 15, 2026
Related Insights
Audiogram
New FDA regulatory initiatives improving rare disease drug development
Sep 23, 2025
Podcast
Rare endpoints: Delivering on unmet patient needs
May 7, 2024
Blog
Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress
May 2, 2024
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Case Study
Speed meets strategy: Delivering a critical FDA 1572 package in just seven days
Sep 9, 2026
Blog
Actioning the commitment letter: The PDUFA VIII changes that matter most to sponsors
Aug 25, 2026
Blog
Data without borders: Assessing China-only evidence for EMA approval – insights from ex-EMA and seasoned subject matter experts
Aug 19, 2026
Blog
The Next Frontier of ADC Development: Navigating an Evolving Regulatory Landscape
Aug 12, 2026
Blog
Japan: the new strategic launchpad for accelerating global rare disease development
Jul 23, 2026
Webinar
From APAC to Global: Designing Data that Travels
Jul 16, 2026
Blog
Regulatory submissions as a source of insight: How AI can amplify the value of our work
Jul 15, 2026